American Diabetes Association and Xeris Pharmaceuticals Join Forces to Combat Hypoglycemia

Collaborative Efforts to Fight Hypoglycemia

In a significant stride toward enhancing diabetes management, the American Diabetes Association (ADA) has established a strategic multi-year partnership with Xeris Pharmaceuticals to address the life-threatening issue of severe hypoglycemia. This collaboration seeks to promote the critical need for all individuals diagnosed with diabetes, especially those receiving insulin, to have access to glucagon, particularly in a ready-to-use formulation. This initiative is aligned with the ADA's updated Standards of Care in Diabetes—2025, which emphasize the importance of glucagon prescriptions for individuals at risk.

Understanding Severe Hypoglycemia

Hypoglycemia, or low blood sugar, poses serious risks for diabetic patients on medication. It's alarming that an estimated 46% of individuals with type 1 diabetes and 21% of those with type 2 diabetes using insulin experience at least one serious hypoglycemic event annually. Such events contribute to more than 200,000 emergency room visits each year, with about 25% necessitating hospitalization. The grave statistics underscore the urgency for proactive measures to educate patients and healthcare providers about the dangers of severe hypoglycemia.